The approach to treating hematological malignancies is rapidly evolving as we discover the underlying mechanisms of disease and identify new immune pathways within the patient’s body to harness.

The determination of cell viability in any cell culture is a crucial analytical measurement for any study. One of the most common ways to measure cell viability is via the determination of the cell membrane’s integrity.

The high resolution and scale that single cell analysis provides is revolutionizing drug discovery and development by introducing comparative, longitudinal and causal information that transforms our ability to understand biology and disease.

Studying tissue and organ biology is challenging, particularly in mammals, given sample accessibility and ethical concerns. However, the use of organoids alleviates these challenges, supporting researchers in exploring questions that previously could not have been investigated without them.

Download this app note to discover immunoassay platforms that are consistent for your cell therapy and immunology development needs.

While the complexity of organoids remains challenging, technological advances are enabling organoids to be developed and monitored in an automated fashion, so that they can be exploited in high-throughput drug screening assays.

With the advances in 3D culture, liver spheroids made from primary human hepatocytes have been demonstrated to be a useful novel tool for in vitro hepatotoxicity studies.

Recently, the advantages of PHH liver spheroids use in liver toxicity tests over the traditional 2D monolayer culture of PHHs has been demonstrated by many scientists.

Affibodies are synthetic antigen-binding proteins. They offer many advantages over monoclonal antibodies, including smaller sizes, enhanced thermal stability and rapid refolding capability. These advantages make affibodies an attractive platform for the development of therapeutics, diagnostics and bioimaging technology.

Viruses exploit high-dimensional RNA structures to facilitate viral replication and impede host restriction. Here, a novel next-generation sequencing (NGS)-based screening workflow, called Fate-seq, was used to define and characterize high-dimensional RNA structures.